Thioridazine and the neuroleptic radioreceptor assay

Richard Mailman, J. P. Pierce, K. M. Crofton, J. Petitto, D. L. DeHaven, C. D. Kilts, M. H. Lewis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

When the neuroleptic radioreceptor assay (NRRA) has been used to monitor total neuroleptic-like activity (NLA) in the blood of patients taking thioridazine, the NLA values obtained from the NRRA are much lower than values calculated in the same sample by measuring the actual concentrations of parent drug and active metabolites and multiplying these values by the relative potency of each compound. The present paper demonstrates that in the NRRA for thioridazine or its active metabolites, the normal displacement of [3H]-spiperone from striatal membranes by thioridazine is altered in the presence of sera. The inclusion of serum (50 μliter/ml) distorts the sigmoidal displacement curves, such that the resulting log-logit (or Hill) slope is markedly decreased. Similar serum-induced changes in the log-logit slope are seen for two active metabolites of thioridazine but not for chlorpromazine of haloperidol. As a consequence, when one of these latter drugs is used as a standard, the NRRA substantially underestimates the actual NLA (chlorpromazine equivalents) values for patients treated with thioridazine. Moreover, because of differences in the magnitude of the effect with serum from different individuals, it is not possible to control completely for this effect. Thus, these data reconcile discrepancies that have been reported for data from the NRRA versus that from direct analytical measurements, and demonstrate that the use of the NRRA as a quantitative tool in the clinical pharmacology of thioridazine may lead to erroneous estimations of active drug and metabolites in the blood.

Original languageEnglish (US)
Pages (from-to)833-847
Number of pages15
JournalBiological Psychiatry
Volume19
Issue number6
StatePublished - 1984

Fingerprint

Thioridazine
Radioligand Assay
Antipsychotic Agents
Chlorpromazine
Serum
Pharmaceutical Preparations
Corpus Striatum
Spiperone
Clinical Pharmacology
Haloperidol
Parents

All Science Journal Classification (ASJC) codes

  • Biological Psychiatry

Cite this

Mailman, R., Pierce, J. P., Crofton, K. M., Petitto, J., DeHaven, D. L., Kilts, C. D., & Lewis, M. H. (1984). Thioridazine and the neuroleptic radioreceptor assay. Biological Psychiatry, 19(6), 833-847.
Mailman, Richard ; Pierce, J. P. ; Crofton, K. M. ; Petitto, J. ; DeHaven, D. L. ; Kilts, C. D. ; Lewis, M. H. / Thioridazine and the neuroleptic radioreceptor assay. In: Biological Psychiatry. 1984 ; Vol. 19, No. 6. pp. 833-847.
@article{c3713918c971482ea1c0f328b97c6edc,
title = "Thioridazine and the neuroleptic radioreceptor assay",
abstract = "When the neuroleptic radioreceptor assay (NRRA) has been used to monitor total neuroleptic-like activity (NLA) in the blood of patients taking thioridazine, the NLA values obtained from the NRRA are much lower than values calculated in the same sample by measuring the actual concentrations of parent drug and active metabolites and multiplying these values by the relative potency of each compound. The present paper demonstrates that in the NRRA for thioridazine or its active metabolites, the normal displacement of [3H]-spiperone from striatal membranes by thioridazine is altered in the presence of sera. The inclusion of serum (50 μliter/ml) distorts the sigmoidal displacement curves, such that the resulting log-logit (or Hill) slope is markedly decreased. Similar serum-induced changes in the log-logit slope are seen for two active metabolites of thioridazine but not for chlorpromazine of haloperidol. As a consequence, when one of these latter drugs is used as a standard, the NRRA substantially underestimates the actual NLA (chlorpromazine equivalents) values for patients treated with thioridazine. Moreover, because of differences in the magnitude of the effect with serum from different individuals, it is not possible to control completely for this effect. Thus, these data reconcile discrepancies that have been reported for data from the NRRA versus that from direct analytical measurements, and demonstrate that the use of the NRRA as a quantitative tool in the clinical pharmacology of thioridazine may lead to erroneous estimations of active drug and metabolites in the blood.",
author = "Richard Mailman and Pierce, {J. P.} and Crofton, {K. M.} and J. Petitto and DeHaven, {D. L.} and Kilts, {C. D.} and Lewis, {M. H.}",
year = "1984",
language = "English (US)",
volume = "19",
pages = "833--847",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "6",

}

Mailman, R, Pierce, JP, Crofton, KM, Petitto, J, DeHaven, DL, Kilts, CD & Lewis, MH 1984, 'Thioridazine and the neuroleptic radioreceptor assay', Biological Psychiatry, vol. 19, no. 6, pp. 833-847.

Thioridazine and the neuroleptic radioreceptor assay. / Mailman, Richard; Pierce, J. P.; Crofton, K. M.; Petitto, J.; DeHaven, D. L.; Kilts, C. D.; Lewis, M. H.

In: Biological Psychiatry, Vol. 19, No. 6, 1984, p. 833-847.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Thioridazine and the neuroleptic radioreceptor assay

AU - Mailman, Richard

AU - Pierce, J. P.

AU - Crofton, K. M.

AU - Petitto, J.

AU - DeHaven, D. L.

AU - Kilts, C. D.

AU - Lewis, M. H.

PY - 1984

Y1 - 1984

N2 - When the neuroleptic radioreceptor assay (NRRA) has been used to monitor total neuroleptic-like activity (NLA) in the blood of patients taking thioridazine, the NLA values obtained from the NRRA are much lower than values calculated in the same sample by measuring the actual concentrations of parent drug and active metabolites and multiplying these values by the relative potency of each compound. The present paper demonstrates that in the NRRA for thioridazine or its active metabolites, the normal displacement of [3H]-spiperone from striatal membranes by thioridazine is altered in the presence of sera. The inclusion of serum (50 μliter/ml) distorts the sigmoidal displacement curves, such that the resulting log-logit (or Hill) slope is markedly decreased. Similar serum-induced changes in the log-logit slope are seen for two active metabolites of thioridazine but not for chlorpromazine of haloperidol. As a consequence, when one of these latter drugs is used as a standard, the NRRA substantially underestimates the actual NLA (chlorpromazine equivalents) values for patients treated with thioridazine. Moreover, because of differences in the magnitude of the effect with serum from different individuals, it is not possible to control completely for this effect. Thus, these data reconcile discrepancies that have been reported for data from the NRRA versus that from direct analytical measurements, and demonstrate that the use of the NRRA as a quantitative tool in the clinical pharmacology of thioridazine may lead to erroneous estimations of active drug and metabolites in the blood.

AB - When the neuroleptic radioreceptor assay (NRRA) has been used to monitor total neuroleptic-like activity (NLA) in the blood of patients taking thioridazine, the NLA values obtained from the NRRA are much lower than values calculated in the same sample by measuring the actual concentrations of parent drug and active metabolites and multiplying these values by the relative potency of each compound. The present paper demonstrates that in the NRRA for thioridazine or its active metabolites, the normal displacement of [3H]-spiperone from striatal membranes by thioridazine is altered in the presence of sera. The inclusion of serum (50 μliter/ml) distorts the sigmoidal displacement curves, such that the resulting log-logit (or Hill) slope is markedly decreased. Similar serum-induced changes in the log-logit slope are seen for two active metabolites of thioridazine but not for chlorpromazine of haloperidol. As a consequence, when one of these latter drugs is used as a standard, the NRRA substantially underestimates the actual NLA (chlorpromazine equivalents) values for patients treated with thioridazine. Moreover, because of differences in the magnitude of the effect with serum from different individuals, it is not possible to control completely for this effect. Thus, these data reconcile discrepancies that have been reported for data from the NRRA versus that from direct analytical measurements, and demonstrate that the use of the NRRA as a quantitative tool in the clinical pharmacology of thioridazine may lead to erroneous estimations of active drug and metabolites in the blood.

UR - http://www.scopus.com/inward/record.url?scp=0021259533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021259533&partnerID=8YFLogxK

M3 - Article

C2 - 6743721

AN - SCOPUS:0021259533

VL - 19

SP - 833

EP - 847

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 6

ER -

Mailman R, Pierce JP, Crofton KM, Petitto J, DeHaven DL, Kilts CD et al. Thioridazine and the neuroleptic radioreceptor assay. Biological Psychiatry. 1984;19(6):833-847.